MedTrace Logo

Anti-CD19 CAR-T Cell Therapy for Patients With Refractory Systemic Lupus Erythematosus

NCT07720310 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2026-07-22

No results posted yet for this study

Summary

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by B-cell dysfunction leading to the production of autoantibodies that play a key role in the onset and progression of the disease. In the treatment of SLE today, glucocorticosteroid hormones, cytostatics (azathioprine, cyclophosphamide, mycophenolate mofetil, hydroxychloroquine, etc.), and biological therapy (rituximab, belimumab) are widely used. However, this therapy has limitations: firstly, it does not always control the autoimmune process and, secondly, it has side effects. Recent global data on the use of CAR T cells in patients with SLE show promising results, including rapid and durable remission, without the need for disease-modifying drugs and glucocorticoids. The use of the so-called academic CAR-T cell products can improve availability and affordability of this therapy option. The aim of this clinical study is to evaluate the efficacy and safety of academic CAR-T cells in refractory SLE patients.

Conditions

  • System Lupus Erythematosus(SLE)

Interventions

BIOLOGICAL

CAR T cells chimeric antigen receptor cells

academical CAR-T product was manufactured using lentiviral vector encoding anti-CD19 CAR.

Sponsors & Collaborators

  • Minsk scientific and practical center of surgery, transplantology and hematology

    collaborator UNKNOWN

  • N.N. Alexandrov National Cancer Centre

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-09
Primary Completion
2028-06-30
Completion
2030-06-30

Countries

  • Belarus

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07720310 on ClinicalTrials.gov